Treatment Preferences among Adult Patients with Atopic Dermatitis

Catherine Shen

Lebrikizumab normalizes the systemic transcriptomic signature when administered in combination with topical corticosteroids in patients with moderate to severe atopic dermatitis

Abhishek Singh

Lebrikizumab improves atopic dermatitis and quality of life in patients with moderate-to-severe atopic dermatitis previously treated with dupilumab: Results from the ADapt Trial

Raj Chovatiya

Skin clearance, duration of treatment-free interval, and safety of tapinarof cream 1% once daily: results from ADORING 3, a 48-week phase 3 trial in adults and children down to 2 years of age with atopic dermatitis

Anna Tallman

Efficacy and Safety of Upadacitinib Through 188 Weeks in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: Phase 3 Randomized Clinical Trial Results

Alan D Irvine

Which signs and symptoms affect the sleep disturbance and quality of life impairment of moderate-to-severe atopic dermatitis? A causal mediation analysis of upadacitinib phase 3 Measure Up 1 and 2 studies

April Armstrong

Patients with lebrikizumab reported long-term improvement of symptoms from POEM in moderate-to-severe atopic dermatitis

Peter Lio

Dupilumab demonstrates a higher benefit-risk score compared with upadacitinib: a structured benefit-risk assessment of the HEADS UP trial

Mike Bastian

Achievement of no-to-minimal itch and sleep improvement with tapinarof cream 1% once daily in two pivotal phase 3 trials in adults and children down to 2 years of age with atopic dermatitis

Anna Tallman

Effectiveness and safety data of dupilumab in adult and adolescent patients with atopic dermatitis: real-world insights 2 years into the GLOBOSTAD multinational prospective observational study

Kwinten Bosman

No meaningful body weight gain in adults with moderate-to-severe atopic dermatitis treated with dupilumab for 1 year

Mike Bastian

Dupilumab reduces caregiver burden and family impact of moderate-to-severe atopic dermatitis among caregivers of pediatric patients: 6-month results from the RELIEVE-AD pediatric study

Dimittri Delevry

Real-World treatment outcomes of systemic treatments for moderate-to-severe atopic dermatitis in children aged less than 12 years: 4-year results from the PEDISTAD Registry

Annie Zhang

Dupilumab improves disease control in pediatric patients with moderate-to-severe atopic dermatitis in clinical practice: 6-month results from the RELIEVE-AD pediatric study

Dimittri Delevry

Dupilumab safety and efficacy up to 3 years in children aged 6 months to 11 years with atopic dermatitis

Randy Prescilla

Lebrikizumab improves atopic dermatitis in adult and adolescent patients with skin of color: 16-week results from the ADmirable study

Maria Rueda

Dupilumab monotherapy provides sustained improvement in quality of life up to 1 year in adults with moderate-to-severe atopic dermatitis

Ana B. Rossi

Sequence of Improvement of Signs, Symptoms, and Quality of Life in Patients With Prurigo Nodularis Receiving Dupilumab

Joseph Zahn

Growth Analysis in Children Aged 6 to 11 Years with Severe Atopic Dermatitis and Impact of 16 Weeks of Dupilumab Treatment on Height

Annie Zhang

Patient-reported outcomes and family impact with roflumilast cream 0.15% in atopic dermatitis: pooled Phase 3 results (INTEGUMENT-1 and INTEGUMENT-2)

Eric Simpson

Integrated safety of dupilumab up to 5 years for the treatment of moderate‑to‑severe atopic dermatitis in infants, children, adolescents, and adults

Ana B. Rossi

Once-daily roflumilast cream 0.15% for the treatment of atopic dermatitis in patients with diverse skin types: pooled subgroup analysis from the Phase 3 INTEGUMENT 1 and -2 trials

Eric Simpson

Efficacy and safety of once-daily roflumilast cream 0.15% for the treatment of atopic dermatitis: pooled results in patients aged 6–17 years from the INTEGUMENT-1/2 Phase 3 clinical trials

Eric Simpson

Long-term upadacitinib safety in moderate-to-severe atopic dermatitis up to 6 years: an integrated analysis with over 9000 patient-years of exposure

Christopher G. Bunick

Abrocitinib for the treatment of adolescents and adults with moderate-to-severe atopic dermatitis: interim results from an expanded access protocol (JADE REAL)

Dr. Matthew Zirwas

Long-Term Efficacy of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis Who Had Prior Exposure to Systemic Therapies: A Post Hoc Analysis of JADE EXTEND

Dr. Michael Ardern-Jones

Effectiveness and safety of upadacitinib in adolescent and adult patients with atopic dermatitis: an interim analysis of 2-year data from an international real-world multicenter retrospective review

Siddhartha Sood

Laboratory safety profile of upadacitinib in adolescent and adult patients with atopic dermatitis: an interim analysis of a real-world retrospective review

Siddhartha Sood

Clinical safety profile of upadacitinib in adolescent and adult patients with atopic dermatitis: a long-term analysis of a real-world retrospective review

Siddhartha Sood

Five-year real-world drug survival of dupilumab for moderate-to-severe atopic dermatitis in adult patients: A Canadian multicenter retrospective study

Siddhartha Sood

68-122k safety results of amlitelimab (an anti-OX40 Ligand antibody) in participants with moderate-to-severe atopic dermatitis from STREAM-AD Phase 2b dose-ranging and withdrawal study

Kassim Rahwai

Hand eczema is independently associated with significant quality of life impact in patients with atopic dermatitis

Jonathon I. Silverberg

The frequency and impact of sleep disturbances in patients with atopic dermatitis vary greatly by age

Jonathon I. Silverberg

68-week safety results of amlitelimab (an anti-OX40 Ligand antibody) in participants with moderate-to-severe atopic dermatitis from STREAM-AD Phase 2b dose-ranging and withdrawal study

Jonathon I. Silverberg

Dupilumab Reduces Caregiver Burden and Family Impact of Moderate-to-Severe Atopic Dermatitis Among Caregivers of Pediatric Patients: 6-Month Results From the RELIEVE-AD Pediatric Study

Dimittri Delevry

Dupilumab Improves Itch and Skin Symptoms in Pediatric Patients With Moderate-to-Severe Atopic Dermatitis in Clinical Practice 6-Month Results From the RELIEVE-AD Pediatric Study

Dimittri Delevry

Dupilumab Improves Disease Control in Pediatric Patients With Moderate-to-Severe Atopic Dermatitis in Clinical Practice: 6-Month Results From the RELIEVE-AD Pediatric Study

Dimittri Delevry

No meaningful body weight gain in adults with moderate-to-severe atopic dermatitis treated with dupilumab for 1 year

Mike Bastian

Dupilumab Demonstrates a Higher Benefit-Risk Score Compared With Upadacitinib: A Structured Benefit-Risk Assessment of the Heads Up Trial

Mike Bastian

Long-Term Upadacitinib Safety in Moderate-to-Severe Atopic Dermatitis up to 6 Years: An Integrated Analysis With Over 9000 Patient-Years of Exposure

Christopher G. Bunick

Effectiveness and safety of upadacitinib in adolescent and adult patients with atopic dermatitis: an interim analysis of 2-year data from an international real-world multicenter retrospective review

Siddhartha Sood

Clinical safety profile of upadacitinib in adolescent and adult patients with atopic dermatitis: an interim analysis of a real-world retrospective review

Siddhartha Sood

Laboratory safety profile of upadacitinib in adolescent and adult patients with atopic dermatitis: an interim analysis of a real-world retrospective review

Siddhartha Sood

Five-year real-world drug survival of dupilumab for moderate-to-severe atopic dermatitis in adult patients: A Canadian multicenter retrospective study

Siddhartha Sood

Lebrikizumab normalizes the systemic transcriptomic signature when administered in combination with topical corticosteroids in patients with moderate to severe atopic dermatitis

Abhishek Singh

Real-World treatment outcomes of systemic treatments for moderate-to-severe atopic dermatitis in children aged less than 12 years: 4-year results from the PEDISTAD Registry

Annie Zhang

Sequence of Improvement of Signs, Symptoms, and Quality of Life in Patients With Prurigo Nodularis Receiving Dupilumab

Joseph Zahn

Growth Analysis in Children 6-11 Years with Severe Atopic Dermatitis and Impact of 16 Weeks of Dupilumab on Height

Annie Zhang

Effectiveness and safety data of dupilumab in adult and adolescent patients with atopic dermatitis: real-world insights 2 years into the GLOBOSTAD multinational prospective observational study

Kwinten Bosman

Dupilumab monotherapy provides sustained improvement in quality of life up to 1 year in adults with moderate-to-severe atopic dermatitis

Ana B. Rossi

Skin clearance, duration of treatment-free interval, and safety of tapinarof cream 1% once daily: results from ADORING 3, a 48-week phase 3 trial in adults and children down to 2 years of age with atopic dermatitis

Anna Tallman

Achievement of no-to-minimal itch and sleep improvement with tapinarof cream 1% once daily in two pivotal phase 3 trials in adults and children down to 2 years of age with atopic dermatitis

Anna Tallman

Integrated Safety of Dupilumab up to 5 Years for the Treatment of Moderate‑to‑Severe Atopic Dermatitis in Infants, Children, Adolescents, and Adults

Ana B. Rossi

Dupilumab Safety and Efficacy up to 3 Years in Children Aged 6 Months to 11 Years with Atopic Dermatitis

Randy Prescilla

Lebrikizumab Improves Atopic Dermatitis and Quality of Life in Patients With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab: Results From the ADapt Trial

Raj Chovatiya

Lebrikizumab Improves Atopic Dermatitis in Adult and Adolescent Patients With Skin of Color: 16-Week Results From the ADmirable Study

Maria Rueda

Patients with lebrikizumab reported long-term improvement of symptoms from POEM in moderate-to-severe atopic dermatitis

Peter Lio

Patient-Reported Outcomes and Family Impact With Roflumilast Cream in Atopic Dermatitis: Pooled Phase 3 Results (INTEGUMENT-1 and INTEGUMENT-2)

Eric Simpson

Once-Daily Roflumilast Cream 0.15% for the Treatment of Atopic Dermatitis in Patients With Diverse Skin Types: Pooled Subgroup Analysis From the Phase 3 INTEGUMENT-1 and -2 Trials

Eric Simpson

Efficacy and Safety of Once-Daily Roflumilast Cream 0.15% for the Treatment of Atopic Dermatitis: Pooled Results in Patients 6 to 17 Years of Age From the INTEGUMENT-1/2 Phase 3 Clinical Trials

Eric Simpson

The frequency and impact of sleep disturbances in patients with atopic dermatitis vary greatly by age

Jonathon I. Silverberg

Long-Term Efficacy of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis Who Had Prior Exposure to Systemic Therapies: A Post Hoc Analysis of JADE EXTEND

Dr. Michael Ardern-Jones

Abrocitinib for the Treatment of Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: Interim Results From an Expanded Access Protocol (JADE REAL)

Dr. Matthew Zirwas